AR420626

AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM) . AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca2+ signal-mediated glucose uptake and improve diabetes[1][2][3][4].

Product Specifications

CAS Number

[1798310-55-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

CaMK; Epigenetic Reader Domain; Free Fatty Acid Receptor; GLUT; HDAC; Histone Methyltransferase; mTOR; nAChR; p38 MAPK; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ar420626.html

Purity

98.29

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC(NC(C2=C(NC(CCC3)=C(C2C4=CC=CO4)C3=O)C)=O)=C(C=C1)Cl

Molecular Formula

C21H18Cl2N2O3

Molecular Weight

417.29

Precautions

H302, H315, H319

References & Citations

[1]Kaji I, et al. Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon. Neurogastroenterol Motil. 2018 Jan;30 (1) :10.1111/nmo.13157. |[2]Mikami, et al. AR420626, a selective agonist of GPR41/FFA3, suppresses growth of hepatocellular carcinoma cells by inducing apoptosis via HDAC inhibition. Therapeutic Advances in Medical Oncology 12 (2020) : 1758835920913432.|[3]Ye-Ji Lee, et al. Free fatty acid 3 receptor agonist AR420626 reduces allergic responses in asthma and eczema in mice. International Immunopharmacology 127 (2024) : 111428.|[4]Do‐Hyung, et al. Gαi‐coupled GPR41 activation increases Ca2+ influx in C2C12 cells and shows a therapeutic effect in diabetic animals. Obesity 31.7 (2023) : 1871-1883.